Efficacy of vorinostat in a murine model of polycythemia vera - Wikidata - wikimedia - TriplyDB

Efficacy of vorinostat in a murine model of polycythemia vera

Efficacy of vorinostat in a murine model of polycythemia vera

http://www.wikidata.org/entity/Q35909673

about

DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics New Therapeutic Approaches in Polycythemia Vera Clinical potential of pacritinib in the treatment of myelofibrosis Transcription factors in late megakaryopoiesis and related platelet disorders Regulation and function of the NFE2 transcription factor in hematopoietic and non-hematopoietic cells Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.Systematic analysis of time-series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors.Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.Myeloproliferative neoplasm animal models Molecular classification of myeloproliferative neoplasms-pros and cons.Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).Fli-1 overexpression in erythroleukemic cells promotes erythroid de-differentiation while Spi-1/PU.1 exerts the opposite effect.Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases.Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms.

P2860

Q26749421-2E2D03F2-2F6F-4B59-AF49-94CE62F16C9A Q26795677-D1C1DBB2-1267-4CA3-8389-10527C824BA5 Q26796450-D484CA98-7C08-497C-A62A-F28B712C9074 Q27015841-F21AA498-36B0-475F-B8B0-93227D4FA5F4 Q29037128-CFD11157-EC96-4CF0-9D95-619965CCB847 Q33407924-34B20286-22C3-4A61-9085-0D62212FD8B8 Q34413200-8F9A94F2-092E-40DB-B315-4DB79E74DB1C Q35726371-59697946-8C04-4AC4-B8B8-252C1E76AD20 Q35856790-52621376-EDB9-45AD-9E92-A17AD63A40B6 Q38046320-C10D7738-9DB1-4D61-AFDF-CD2EED117FD0 Q38148982-8185C78C-989F-475F-A859-358935EB0461 Q38699339-67593E80-75F4-4746-93A7-1791D4C65565 Q38701165-05B5C755-72B3-433E-8E25-256A2B9CBF1D Q38984578-90D5B694-9D50-4046-AC65-9BCDB8560614 Q39403830-3E8C9DA8-3F0F-4F2D-B996-0DB2C6027A80 Q45948898-2D4CC69B-ABC4-4565-8732-4793867BFB8F Q55071119-BE786B56-C0FC-4BF6-88AF-CCA4989C4EFA

P2860

Efficacy of vorinostat in a murine model of polycythemia vera

http://www.wikidata.org/entity/Q35909673

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Efficacy of vorinostat in a murine model of polycythemia vera

@ast

Efficacy of vorinostat in a murine model of polycythemia vera

@en

type

label

Efficacy of vorinostat in a murine model of polycythemia vera

@ast

Efficacy of vorinostat in a murine model of polycythemia vera

@en

prefLabel

Efficacy of vorinostat in a murine model of polycythemia vera

@ast

Efficacy of vorinostat in a murine model of polycythemia vera

@en

P1433

Q35909673-BDEB5421-D815-455A-A762-BF5CBA09A634

P1476

Q35909673-8D457669-7E07-426A-8EA7-A8CEFB26C987

P2093

Q35909673-5FC3BF98-C045-4684-8B04-56FA93E42E00

Q35909673-6E68FAA8-1462-40E2-B59E-F3F08402C380

Q35909673-72D2CFC2-40F4-4DFC-BAAC-CBEB46C13AB6

Q35909673-7EAF3127-08CA-45B4-B435-E6CDF7F90EBE

Q35909673-AC2DC621-C6E0-4221-BC2E-FA9066FAB0EA

Q35909673-B9EAE417-787E-4C4F-8166-A265F439D0DF

Q35909673-C7AE3C5D-7BB5-4F59-B9AF-A326A54C1113

P2860

Q35909673-02045FD9-9B2E-434E-9989-1735ECA15352

Q35909673-08D4EB68-A221-4DEA-85A2-7A53BD6BE4B6

Q35909673-1A761DF6-67B5-4FEE-989A-BBD937F4E77E

Q35909673-1C472376-9C76-4AFC-8B66-8BC8BCF1E5FF

Q35909673-1F2A4ABC-72FE-45E9-9174-A526FB39ACD2

Q35909673-25C91288-F012-41B8-A47C-C084AD80F6BC

Q35909673-288DE790-747E-4E24-8EB6-03F662442396

Q35909673-2BAB44A8-417B-4C60-BD1D-91800DB37018

Q35909673-312BFF3F-B347-4F2A-8B7D-5B74FCF993C1

Q35909673-3C7E57B6-0F81-443B-BC33-1B4B7733DAAC

P304

Q35909673-9D517F4C-2212-4611-9C1F-83B8D8CED01A

P31

Q35909673-184E4FBA-523D-4630-9CD1-4291DDD23D95

P356

Q35909673-1C97275C-D380-4527-B467-49607CDD6419

P407

Q35909673-0BEB059A-E8D1-4228-9D90-619EA008AA1C

P433

Q35909673-A21AFE40-CA1F-460E-AAEE-C4525AB4CFCF

P478

Q35909673-91F2D460-F1F0-4A3F-A2B6-281211043FE0

P577

Q35909673-9FB15EBC-6B6C-4E7C-BD45-1C86DCA9B128

P5875

Q35909673-C123CB4E-62A7-44C4-8886-C1FB34E58A48

P698

Q35909673-3724C446-7048-41D4-ABAD-ECC6E2E07399

P932

Q35909673-69277450-5603-4205-BEFF-AFDC2B9B7293

P356

BLOOD-2011-02-336743

P1433

P1476

Efficacy of vorinostat in a murine model of polycythemia vera

@en

P2093

Ajeet Gajra

http://www.w3.org/2001/XMLSchema#string

Alicia Bair

http://www.w3.org/2001/XMLSchema#string

Golam Mohi

http://www.w3.org/2001/XMLSchema#string

Hajime Akada

http://www.w3.org/2001/XMLSchema#string

Robert E Hutchison

http://www.w3.org/2001/XMLSchema#string

Saeko Akada

http://www.w3.org/2001/XMLSchema#string

Stephen Graziano

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Jak2 is essential for signaling through a variety of cytokine receptors

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

Differential biological activity of disease-associated JAK2 mutants

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

P304

3779-3789

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-02-336743

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221694233

http://www.w3.org/2001/XMLSchema#string

P698

22408262

http://www.w3.org/2001/XMLSchema#string

P932

3335382

http://www.w3.org/2001/XMLSchema#string